


Dr. Singh has consulted for Janssen Pharmaceuticals Inc. on a once-daily medication, canagliflozin (Sodium Glucose co-Transporter Inhibitor-2) safety. He was compensated for his time. None of the other authors has any potential conflicts of interest and there are no financial disclosures to make.

A handwritten signature in black ink, appearing to read "John", followed by a period.